Skip to content

A Controlled Study of an Herbal Topical Patch in Treating Osteoarthritis (OA) of the Knee

A Multi-Center, Randomized, Double-Blind, Parallel, Placebo Control Study of a Traditional Chinese Medicine Topical Analgesic Patch in the Treatment of Osteoarthritis of the Knee

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01183624
Enrollment
626
Registered
2010-08-17
Start date
2010-07-31
Completion date
2011-04-30
Last updated
2016-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Keywords

Osteoarthritis, Pain, Herbal medicine, Topical administration

Brief summary

An evaluation of the safety and efficacy of an herbal patch in treating osteoarthritis pain of the right or left knee.

Detailed description

This is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study of herbal patch in subjects with OA knee pain. The overall objective of this study is to evaluate the efficacy and safety of the patch in relieving OA knee pain.

Interventions

1 herbal patch applied for approximately 8 hours per day for 14 days

OTHERPlacebo Patch

Control patch with no herbal ingredients

Sponsors

Johnson & Johnson Consumer and Personal Products Worldwide
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Male or female between 40 and 70 years of age * Medically cleared to participate by a site affiliated physician following a physical * History of, or current diagnosis of, OA of the knee * Evidence of idiopathic OA of at least one knee * Subject Assessment of OA pain in target knee 40 - 75 mm (on the 100 mm VAS inclusive) in the index knee, on the WOMAC Pain composite subscale at Visit 1 * Subject Assessment of OA pain in non-index knee (if applicable) is ≤ 20mm * Subject Global Assessment of OA Condition (5 pt categorical scale, 1 = very good to 5 = very poor) of grade 3-5 (i.e. fair, poor or very poor) * Evidence of idiopathic OA of at least one knee as defined by the American College of Rheumatology Classification (ACR) of OA of the Knee

Exclusion criteria

* Grade 1 or Grade 4 severity of the index knee based on the Kellgren and Lawrence radiographic criteria * Pain greater than 20 mm on the VAS in the non-index knee (either at rest or with movement) * Prior injection or arthroscopy of study knee within 3 months * Crystalline-induced synovitis (e.g. gout, pseudo gout, nonsteroid arthritis, hydroxyapatite deposit), acute inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, septic arthritis, fibromyalgia, systemic lupus, erythematosus collagen vascular disease or other types of inflammatory arthritis in the index knee * Pain in either knee is of neurological origin * An injury or surgery to the same body region within the prior 6 months or a lifetime history of 3 or more injuries/surgeries to the injured body region * Signs of clinically important active inflammation of the study knee joint including redness, warmth, and/or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits * Other criteria that - in the opinion of the investigator - may jeopardize the safety of the subject or the study results.

Design outcomes

Primary

MeasureTime frameDescription
Pain ScoreDay 7The WOMAC (Western Ontario and McMaster Universities Index of Osteoarthritis) Pain Subscale Score

Secondary

MeasureTime frameDescription
Subject AssessmentDay 3Subject Global Assessment of Response to Treatment: WOMAC Physical Function Subscale and Subject Global Assessment of OA Condition
Investigator AssessmentDay 3Investigator Global TCM Assessment of OA Condition: WOMAC Stiffness Subscale, Total WOMAC Index

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026